Brentuximab Vedotin May Improve Outcomes in Anaplastic Large Cell Lymphoma
Researchers sought to determine whether adding brentuximab vedotin to chemotherapy would be safe and effective in pediatric patients with ALCL.
Hematologic Cancers
Immunotherapeutic Potential of RNA-Modifying Drugs and MicroRNAs in Acute Myeloid Leukemia
Researchers reviewed epitranscriptomics and the prospects of precision medicines that target AML-associated genes.
Survival Rates Not Improving for AYAs With Sarcomas or Breast, Gynecologic Cancers
Survival improvements were noted in brain and nervous system cancers, colorectal cancers, and lung cancer.
Racial Disparities Persist in Multiple Myeloma Care, Outcomes
Hispanics have higher MM-related in-hospital mortality; recent decline seen in in-hospital mortality for all except NH-Blacks.
Calaspargase and Pegaspargase Produce Comparable Results in Newly Diagnosed Acute Lymphoblastic Leukemia
Efficacy and toxicity outcomes were similar with calaspargase and pegaspargase.
Risk of Cardiovascular Death in Patients With Primary Central Nervous System Lymphoma
Risk of CVD death is lower with PCNSL than with extra-central nervous system lymphoma; however, the risk with this rare non-Hodgkin lymphoma is uncertain.
Cryopreservation of Unrelated Donor SCTs Safe, Effective in Patients Who Underwent HSCT
Researchers sought to determine whether cryopreservation of unrelated donor hematopoietic stem cells would affect outcomes in patients who underwent HSCT since the COVID-19 pandemic.
Treatment Strategies and Challenges in Chronic Lymphocytic Leukemia
Researchers sought to clarify the current treatment strategies and challenges for patients with chronic lymphocytic leukemia.
Subcutaneous Daratumumab Associated With Reduced Active Provider Time for Patients With Multiple Myeloma
Researchers sought to determine whether subcutaneous daratumumab would require less HCP time and would be a more efficient method for administering the drug.
Loncastuximab Tesirine ‘Could Change Practice’ for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The antibody-drug conjugate demonstrated durable antitumor activity in heavily pretreated patients.
- Loading...
Loading...
Loading... 
Loading...